Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. (NASDAQ: GCTK) generates news primarily around its progress in implantable continuous blood glucose monitoring technology for people with diabetes and the financing activities that support this development. As a medical device and medical technology company, GlucoTrack regularly issues updates on clinical studies, advisory appointments, scientific presentations, and capital formation transactions.
Visitors to this GCTK news page can review press releases on clinical milestones, including GlucoTrack’s first-in-human study of its long-term implantable Continuous Blood Glucose Monitor (CBGM) and the initiation of a long-term, multicenter feasibility study outside the United States. The company also reports on its plans and interactions related to Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, as described in its own forward-looking statements.
In addition to clinical updates, GlucoTrack publishes news about its clinical advisory team and patient engagement efforts, such as the appointment of specialists in cardiology, neuromodulation, and pain management, and the formation of a Patient Advisory Board. The company’s participation in diabetes-focused conferences and research initiatives, where it presents data on its blood-based, implantable CBGM system and epidural glucose monitoring work, is another frequent topic.
GlucoTrack’s news flow also covers financing and capital structure developments, including equity purchase agreements, private placements, and warrant repurchases described in its press releases and SEC filings. For investors and observers following GCTK, this page offers a consolidated view of GlucoTrack’s publicly disclosed corporate, clinical, and financial announcements related to its investigational CBGM platform and broader diabetes technology strategy.
Glucotrack (NASDAQ: GCTK) has announced a 1-for-20 reverse stock split effective February 4, 2025. The company's outstanding common stock will be reduced from 155,491,473 to approximately 7,774,574 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares, which will be rounded up to the next whole share.
The reverse split, approved by stockholders on January 3, 2025, and ratified by the Board on January 28, 2025, aims to bring Glucotrack into compliance with Nasdaq's $1.00 minimum bid price requirement and attract institutional investors. The company's stock will continue trading on Nasdaq under the symbol 'GCTK' with a new CUSIP number 45824Q705.
VStock Transfer, will serve as the exchange agent, managing the automatic share adjustment process and sending transaction statements to stockholders. Those holding shares through brokers will have their positions automatically adjusted according to their broker's processes.
Glucotrack (Nasdaq: GCTK) has appointed Peter C. Wulff as Chief Financial Officer, effective immediately. Wulff brings over 35 years of financial management experience in the emerging growth life sciences sector, with expertise in both public and private companies.
Wulff's track record includes successful capital raising through public and private equity offerings, debt financing, and strategic business transactions. He previously served as CFO at Biological Dynamics, Inc. and JenaValve Technology, Inc., where he managed the company's corporate relocation from Germany and various capital raise transactions. His experience also includes financial leadership roles at Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences.
The appointment aims to support Glucotrack's commercialization of its continuous blood glucose monitor for people with diabetes, with focus on driving financial excellence and advancing the company's strategic vision.
Glucotrack (Nasdaq: GCTK) has achieved ISO 13485:2016 certification from the British Standards Institute (BSI), marking a significant milestone in its development of continuous blood glucose monitoring technology. The certification validates the company's quality management system for medical device design and development.
The achievement follows successful completion of Stage I and Stage II Assessments by BSI, confirming Glucotrack's compliance with ISO 13485:2016 standards. This internationally recognized certification is particularly significant given the FDA's 2024 Quality Management System Regulation Final Rule, which aligns U.S. requirements with global standards through ISO 13485 adoption.
CEO Paul V. Goode emphasized this certification's importance in their journey toward delivering high-quality Continuous Blood Glucose Monitor (CBGM) products for people with diabetes, highlighting the company's commitment to quality and regulatory excellence.
Glucotrack (Nasdaq: GCTK) has appointed Ted Williams as Vice President of Regulatory Affairs, effective immediately. Williams brings nearly 25 years of experience in regulatory affairs and quality assurance for Class III medical devices, including expertise in continuous glucose monitors (CGM) and drug/device combination products.
Williams previously served as Vice President of Regulatory Affairs/Quality Assurance at Glysens Inc, focusing on implantable CGM development. His experience spans roles at Therapeutics Inc. and Cardium Therapeutics, working with various medical technologies.
The appointment aims to advance Glucotrack's human clinical trials and regulatory program for their Continuous Blood Glucose Monitor (CBGM). According to CEO Paul V. Goode, Williams' expertise will be important in navigating FDA pathways as they develop their CBGM technology for diabetes patients.
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes care technologies, has announced its participation in the upcoming TechBio Showcase™ 2025. The company's President and CEO, Paul V. Goode, will deliver a corporate update focusing on their Continuous Blood Glucose Monitor (CBGM) technology.
The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite C track. TechBio Showcase, part of Biotech Showcase™ 2025, is organized by Demy-Colton and EBD Group. This investor conference serves as a networking platform for executives and investors, promoting geographical investment and partnership opportunities in therapeutic development.
Glucotrack (NASDAQ: GCTK) has initiated patient enrollment for a short-term human clinical study of its continuous blood glucose monitor (CBGM). The study includes both type 1 and type 2 diabetes patients, with results expected in 6-8 weeks. The CBGM is a long-term implantable device that measures glucose directly from blood, designed to work for three years without external components. The four-day in-hospital study is being conducted at Instituto do Coração under Dr. Alexandre Abizaid, involving intravascular sensor placement and fixed meal challenges.
Glucotrack (Nasdaq: GCTK) has completed a $10.0 million public offering and concurrent private placement. The offering included 2,437,340 shares of common stock and 4,756,900 pre-funded warrants at $1.39 per share. Each share and warrant came with series A and B common warrants exercisable at $1.81 per share. Additionally, the company converted $4.0 million in outstanding secured convertible notes from July 2024 into equity on similar terms. Dawson James Securities acted as the sole placement agent for the public offering.
Glucotrack (Nasdaq: GCTK) announced a $10.0 million public offering of approximately 7,195,000 shares of common stock or pre-funded warrants at $1.39 per unit. Each unit includes series A and B common warrants exercisable at $1.81 per share. Additionally, the company will convert approximately $4.0 million in outstanding secured convertible notes from July 2024 in a concurrent private placement. The offering is expected to close on November 14, 2024, with Dawson James Securities acting as the sole placement agent.
Glucotrack (Nasdaq: GCTK), a medical technology company focusing on diabetes technologies, will participate in the 2024 BioFuture Conference in New York City from October 28-30, 2024. Paul V. Goode, President & CEO, will present on October 29 at 11:00 AM ET, providing an update on the company's continuous blood glucose monitor (CBGM) development.
The BioFuture Conference will explore topics such as quantum computing in biology, alternative financing, AI in healthcare, psychedelics in mental health treatments, and bioethical challenges. Speakers from prominent companies like Regeneron Pharmaceuticals, IBM, and JP Morgan will discuss major trends shaping healthcare's future.
Qualified investors and media can apply for complimentary registration to attend the conference, which will feature over 100 future-focused presentations.
Glucotrack, Inc. (Nasdaq: GCTK) announced that updated preclinical data for its continuous blood glucose monitor (CBGM) will be presented at the 24th Annual Diabetes Technology Meeting from October 15-17, 2024, in Burlingame, California. Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver an oral presentation titled "The Technology Behind Continuous Blood Glucose Monitoring" on October 17.
The company will also present two posters: "In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model" and "Exploratory Study of Continuous Glucose Monitoring in the Epidural Space in Swine". These presentations aim to showcase the CBGM's ability to accurately measure glucose levels without the lag time associated with interstitial glucose and without an on-body wearable, potentially offering a less intrusive approach for people with diabetes.